Overexpressed oncogenic tumor-self antigens

Area of Science:

• Oncology
• Immunology
• Vaccine Development

Background:

• Overexpressed tumor-self antigens are a major focus for cancer vaccine development.
• Antigens involved in oncogenesis are underexplored but highly promising vaccine targets.
• Previous assumptions suggested immune tolerance and autoimmunity would hinder vaccine strategies against self antigens.

Purpose of the Study:

• To review vaccine efforts targeting tumor-self antigens, particularly those involved in oncogenesis.
• To highlight TPD52 as a novel and promising vaccine target.
• To demonstrate that immune tolerance and autoimmunity can be overcome in cancer vaccine development.

Main Methods:

• Review of preclinical and clinical vaccine studies.
• Focus on vaccine strategies for known tumor-self antigens.
• In-depth examination of TPD52 as a potential vaccine target.

Main Results:

• Vaccine development against tumor-self antigens, including those in oncogenesis, is feasible.
• Immune tolerance and autoimmunity are surmountable obstacles in developing these vaccines.
• TP52 emerges as a significant candidate for cancer vaccine strategies.

Conclusions:

• Tumor-self antigens, especially those driving oncogenesis, represent a viable class for cancer vaccines.
• Preclinical and clinical data support the successful development of vaccines against self antigens.
• Further research into understudied mechanisms of tolerance is needed for broader vaccine application, potentially with adjuvant therapy or in low tumor burden settings.